Marc Wilson
Director of Finance/CFO bei CRINETICS PHARMACEUTICALS, INC.
Vermögen: 5 Mio $ am 31.03.2024
Profil
Marc J.
S.
Wilson is currently the Chief Financial Officer at Crinetics Pharmaceuticals, Inc. He previously held the position of Accounting Director & Controller at Trius Therapeutics, Inc. from 2010 to 2014, and Chief Accounting Officer & Vice President at Cidara Therapeutics, Inc. from 2014 to 2018.
Mr. Wilson completed his undergraduate degree at the College of the Holy Cross (Massachusetts).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.03.2024 | 110 630 ( 0,14% ) | 5 Mio $ | 31.03.2024 |
Aktive Positionen von Marc Wilson
| Unternehmen | Position | Beginn |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Director of Finance/CFO | 01.01.2018 |
Ehemalige bekannte Positionen von Marc Wilson
| Unternehmen | Position | Ende |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 03.01.2018 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Comptroller/Controller/Auditor | 01.01.2014 |
Ausbildung von Marc Wilson
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CIDARA THERAPEUTICS, INC. | Health Technology |
| CRINETICS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
